 REHOVOT, Israel, May 27, 2021 PRNewswire -- CollPlant NASDAQ: CLGN, a regenerative and aesthetic medicine company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on the Companys business developments. CollPlant reported revenues of 14.5 million for the first quarter of 2021, a 2,281 increase from the 609,000 recorded in the first quarter of 2020 resulting primarily from the 14 million upfront payment received from Allergan Aesthetics, an AbbVie company, in connection with the development agreement entered into in February 2021. 